

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

*(A joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1763)**

### VOLUNTARY ANNOUNCEMENT SIGNIFICANT PROGRESS MADE IN THE SCIENTIFIC RESEARCH PROJECTS OF CNNC HIGH ENERGY

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, CNNC High Energy Equipment (Tianjin) Co., Ltd. (中核高能(天津)裝備有限公司) (“**CNNC High Energy**”), a subsidiary of the Company, has made significant progress in its scientific research projects.

The research and production project of the mobile digital medical X-ray radiography system under development by CNNC High Energy has achieved significant results, and the product developed and produced under the project has obtained the medical device registration certificate. This product is characterized with advanced image algorithms, excellent mobile performance, compact structure design and simple software process, which will provide clearer clinical diagnostic images, help doctors provide better treatment options for patients and provide better medical services for patients.

The Smart Cobalt-60-based Cone Beam Focused Stereotactic Therapy System under development by CNNC High Energy has also made significant progress, which has successfully completed the product test and obtained the type test report. The product will enter the clinical trial stage successfully. This product can be used to systemically diagnose and treat patients, and is equipped with a gamma knife device with CBCT image guidance system, which will provide clinical patients with “more accurate, faster, stronger and more intelligent” medical services. CNNC High Energy will make every effort to prepare for clinical trials and provide on-site support during the clinical process, so as to lay a solid foundation for the product to obtain the registration certificate as soon as possible and meet the conditions for marketing.

By order of the Board  
**China Isotope & Radiation Corporation**  
**Wang Suohui**  
*Chairman*

Beijing, the PRC, 14 June 2023

*As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Dai Shuquan, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Hui Wan Fai, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.*